secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001326732-26-000036
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor reports final Phase 1 data for XmAb942; predicts superior TL1A inhibition vs first-gen antibodies
--------------------------------------------------------------------------------

- XmAb942 achieved 74.1-day half-life; supports single SC dose every 12 weeks during maintenance.
- Modeling predicts >99% TL1A inhibition in 86% of patients during induction vs 31-40% for first-gen.
- No serious TEAEs; ADA incidence 57% across doses but 0% neutralizing at high-dose tested in Phase 2b.
- Global Phase 2b XENITH-UC enrollment on track; primary endpoint results expected H2 2027.
- First-in-human study for XmAb412 (TL1A x IL23p19) on track to start in Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000036/0001326732-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000036/xncr-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001326732-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer